Insulin Aspart
Brand name: Novolog Flexpen
Rank #21 of 500 drugs by total cost
$831.6M
Total Cost
958,823
Total Claims
$831.6M
Total Cost
29,922
Prescribers
$867
Cost per Claim
161,779
Beneficiaries
1,529,552
30-Day Fills
$28K
Avg Cost/Provider
32
Avg Claims/Provider
About Insulin Aspart
Insulin Aspart (sold as Novolog Flexpen) was prescribed 958,823 times by 29,922 Medicare Part D providers in 2023, costing the program $831.6M. At $867 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 18 | Ibrutinib (Imbruvica) | $875.8M | 56,368 |
| 19 | Ustekinumab (Stelara) | $852.3M | 31,974 |
| 20 | Paliperidone Palmitate (Invega Sustenna) | $832.3M | 252,388 |
| 21 | Insulin Aspart (Novolog Flexpen) | $831.6M | 958,823 |
| 22 | Budesonide/Formoterol Fumarate (Symbicort) | $759.4M | 1,452,561 |
| 23 | Palbociclib (Ibrance) | $755.1M | 48,329 |
| 24 | Nintedanib Esylate (Ofev) | $703.7M | 53,928 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology